Synergistic effects of topoisomerase I inhibitor, 7-ethyl-10-hydroxycamptothecin, and irradiation in a cisplatin-resistant human small cell lung cancer cell line

被引:0
|
作者
Kohara, H [1 ]
Tabata, M [1 ]
Kiura, K [1 ]
Ueoka, H [1 ]
Kawata, K [1 ]
Chikamori, M [1 ]
Aoe, K [1 ]
Chikamori, K [1 ]
Matsushita, A [1 ]
Harada, M [1 ]
机构
[1] Okayama Univ, Sch Med, Dept Internal Med 2, Okayama 7008558, Japan
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
7-ethyl-10-[4-(1-piperidyl)-1-piperidyl] carbonyloxy-camptothecin, a topoisomerase I (topo I) inhibitor, is one of the most active agent against lung cancer, and its radiosensitizing effect has been reported recently. We evaluated a combination in vitro effect of irradiation and 7-ethyl-10-hydroxy-CPT (SN-38), an active metabolite of 7-ethyl-10-[4- (1-piperidyl)-1-piperidyl] carbonyloxy-camptothecin, on a human small cell lung cancer cell line (SBC-3) and its cisplatin-resistant subline (SBC-3/CDDP). Growth-inhibitory effects of irradiation with or without SN-38 were determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. A modified isobologram method was used to evaluate the treatment interaction. The combination of irradiation and SN-38 showed a synergistic inhibitory effect on the growth of SBC-3/CDDP despite its cross-resistance to irradiation and SN-38. In contrast, the same combination showed only an additive effect on the growth of parental SBC-3 cells. There was no significant difference in topo I protein expression between these two cell lines. In SBC-3 cells, topo I catalytic activity was suppressed by 4 Gy of irradiation, without a decrease of nuclear topo I protein, whereas the exposure of SBC-3 cells to 1 muM SN-38 subsequent to irradiation showed no remarkable additional effects on both topo I activity and protein content. On the other hand, in SBC-3/CDDP cells, topo I activity was unchanged by irradiation, but the subsequent exposure to SN-38 gave rise to a decrease in topo I activity, which was accompanied by a significant decrease in the topo I protein content (P = 0.02). These observations may indicate that SN-38 induces sequestration of topo I onto DNA in radiation-treated SBC-3/CDDP cells and suggest that the synergistic effect of irradiation and SN-38 in SBC-3/CDDP cells was considered attributable to DNA repair-related enhanced recruitment of topo I onto the damaged DNA.
引用
收藏
页码:287 / 292
页数:6
相关论文
共 50 条
  • [41] Effects of Nivolumab and Ipilimumab on the suppression of cisplatin resistant small cell lung cancer cells
    Wei Chi
    Lianyong Zhang
    Xue Wang
    Jingjing Li
    Fei Li
    Yuxia Ma
    Qianyun Zhang
    Investigational New Drugs, 2022, 40 : 709 - 717
  • [42] Effects of Nivolumab and Ipilimumab on the suppression of cisplatin resistant small cell lung cancer cells
    Chi, Wei
    Zhang, Lianyong
    Wang, Xue
    Li, Jingjing
    Li, Fei
    Ma, Yuxia
    Zhang, Qianyun
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (04) : 709 - 717
  • [43] A Novel Inhibitor of Topoisomerase I Is Selectively Toxic for a Subset of Non-Small Cell Lung Cancer Cell Lines
    Zubovych, Iryna O.
    Sethi, Anirudh
    Kulkarni, Aditya
    Tagal, Vural
    Roth, Michael G.
    MOLECULAR CANCER THERAPEUTICS, 2016, 15 (01) : 23 - 36
  • [44] Growth inhibitory effects of antifolates against an adriamycin-resistant human small cell lung cancer cell line
    Matsuo, K
    Kiura, K
    Ueoka, H
    Tabata, M
    Shibayama, T
    Matsumura, T
    Takigawa, N
    Hiraki, S
    Harada, M
    ACTA MEDICA OKAYAMA, 1997, 51 (03) : 121 - 127
  • [45] Cancer stem cells and cisplatin-resistant cells isolated from non-small-lung cancer cell lines constitute related cell populations
    Lopez-Ayllon, Blanca D.
    Moncho-Amor, Veronica
    Abarrategi, Ander
    Ibanez de Caceres, Inmaculada
    Castro-Carpeno, Javier
    Belda-Iniesta, Cristobal
    Perona, Rosario
    Sastre, Leandro
    CANCER MEDICINE, 2014, 3 (05): : 1099 - 1111
  • [46] Cannabidiol Inhibits Tumorigenesis in Cisplatin-Resistant Non-Small Cell Lung Cancer via TRPV2
    Misri, Swati
    Kaul, Kirti
    Mishra, Sanjay
    Charan, Manish
    Verma, Ajeet Kumar
    Barr, Martin P.
    Ahirwar, Dinesh K.
    Ganju, Ramesh K.
    CANCERS, 2022, 14 (05)
  • [47] Abrogated energy-dependent uptake of cisplatin in a cisplatin-resistant subline of the human ovarian cancer cell line IGROV-1
    Ma, JG
    Maliepaard, M
    Kolker, HJ
    Verweij, J
    Schellens, JHM
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1998, 41 (03) : 186 - 192
  • [48] Overexpression of constitutive signal transducer and activator of transcription 3 mRNA in cisplatin-resistant human non-small cell lung cancer cells
    Ikuta, K
    Takemura, K
    Kihara, M
    Nishimura, M
    Ueda, N
    Naito, S
    Lee, E
    Shimizu, E
    Yamauchi, A
    ONCOLOGY REPORTS, 2005, 13 (02) : 217 - 222
  • [49] Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells
    Li, Amin
    Cao, Weiya
    Liu, Xueke
    Zhang, Yinci
    Ma, Yongfang
    Xu, Ruyue
    Zhang, Rongbo
    Liu, Xinkuang
    Zhou, Shuping
    Wang, Ruikai
    Liu, Jiachang
    Tang, Xiaolong
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2020, 146 (07) : 1737 - 1749
  • [50] Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells
    Amin Li
    Weiya Cao
    Xueke Liu
    Yinci Zhang
    Yongfang Ma
    Ruyue Xu
    Rongbo Zhang
    Xinkuang Liu
    Shuping Zhou
    Ruikai Wang
    Jiachang Liu
    Xiaolong Tang
    Journal of Cancer Research and Clinical Oncology, 2020, 146 : 1737 - 1749